Quick Answer
C4 Therapeutics, Inc. reported Long Term Debt of $0.00 for the year ending 2023.
- C4 Therapeutics, Inc. showed a decrease of -100.0% in Long Term Debt from 2022 to 2023.
- This data is from C4 Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 22, 2024.
- XBRL data for this metric is available from 2020 to 2023 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $9.88 million | Q1 2021: $10.23 million | Q2 2021: $10.41 million | Q3 2021: $10.59 million | Q1 2022: $10.19 million | Q2 2022: $10.37 million | Q3 2022: $9.05 million | Q1 2023: $8.62 million | Q2 2023: $0.00 | Q3 2023: $0.00.
- Over the full 4 years of available data (2020 to 2023), C4 Therapeutics, Inc.'s Long Term Debt has declined by 100.0%.
- Historical annual values: Fiscal year 2023: $0.00 | Fiscal year 2022: $9.20 million | Fiscal year 2021: $10.77 million | Fiscal year 2020: $10.05 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: